CreatorsPublishersAdvertisers

#Eua

COVID: Not everyone will need a booster, experts say

(CNN) — Advisers from the US Food and Drug Administration voted unanimously to recommend emergency authorization of a booster dose of Moderna’s Covid-19 vaccine, and a day later did so again for a booster of Johnson & Johnson’s vaccine. The group voted Friday to authorize a booster shot of Johnson...
PHARMACEUTICALS
Picture for COVID: Not everyone will need a booster, experts say
contagionlive.com

A Review of the Currently Available Monoclonal Antibodies for COVID-19

Outside of vaccines, these underutilized therapies are the best defense against severe disease. Monoclonal antibodies have recently been developed as therapeutic options for the treatment and potential prophylaxis for COVID-19. These specific proteins are made to simulate one of the many defenses of the human immune system. Multiple different monoclonal antibodies have been developed that bind to the spike protein of the SARS-CoV-2 virus, which helps prevent viral attachment and entry into human cells.
SCIENCE
Picture for A Review of the Currently Available Monoclonal Antibodies for COVID-19
TRENDING TOPICS

Why Moderna Stock Fell Today

"The Wall Street Journal" reported that the FDA is delaying a decision on EUA for Moderna's vaccine in adolescents. This bad news was partially offset by an FDA advisory panel recommending EUA for a Moderna vaccine booster. What happened. Shares of Moderna (NASDAQ:MRNA) were falling 3.3% as of 3:34 p.m....
STOCKS

More Covid-19 boosters are on the horizon. But not everyone will need one, experts say

By Travis Caldwell, CNN Advisers from the US Food and Drug Administration voted unanimously to recommend emergency authorization of a booster dose of Moderna’s Covid-19 vaccine, and a day later did so again for a booster of Johnson & Johnson’s vaccine. The group voted Friday to authorize a booster shot of Johnson & Johnson’s vaccine The post More Covid-19 boosters are on the horizon. But not everyone will need one, experts say appeared first on KION546.
PUBLIC HEALTH

Why Ocugen Stock Is Skyrocketing This Week

India granted Emergency Use Authorization to COVID-19 vaccine Covaxin for kids ages two to 18. NDTV reported that the World Health Organization is likely to soon authorize Covaxin. These developments appear to have initiated a short squeeze in Ocugen stock. What happened. Shares of Ocugen (NASDAQ:OCGN) were skyrocketing 41.4% this...
STOCKS

The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO

Here's a roundup of top developments in the biotech space over the last 24 hours. Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For Use In Select Population. Moderna, Inc. (NASDAQ: MRNA) confirmed the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee recommended that the...
MEDICAL & BIOTECH
msn.com

What to know about Bay Area kids ages 5 to 11 and COVID vaccines

The wait for kids ages 5 to 11 to be eligible for the COVID-19 vaccine is nearly over. Pfizer applied for emergency use authorization of its vaccine for this age group earlier this month, and the White House on Tuesday told states to prepare to get shots into the arms of children.
KIDS
massdevice.com

Cepheid wins CE Mark for COVID-19, flu, RSV combo diagnostic

Cepheid announced today that it received CE mark approval for its Xpert Xpress CoV-2/Flu/RSV Plus rapid molecular diagnostic. Sunnyvale, California-based Cepheid last month received FDA emergency use authorization (EUA) for the Xpert Xpress CoV-2/Flu/RSV Plus diagnostic. The company designed its Xpert Xpress Plus as a rapid molecular diagnostic test for...
SUNNYVALE, CA

FDA panel recommends Moderna booster shot EUA for certain people

A Food and Drug Administration advisory panel has unanimously recommended granting emergency use authorization for a third Moderna shot, though only some people would be eligible for the booster shot. The recommendation follows Moderna’s second-quarter financial details shared in August, which included information on the COVID-19 vaccine’s efficacy six months after the second dose, as well as the booster for … Continue reading
HEALTH

FDA will review Merck COVID-19 pill

The U.S. Food and Drug Administration announced on Thursday that it will meet on Nov. 30th to review Merck's experimental oral antiviral COVID-19 treatment. Why it matters: An oral antiviral drug designed to prevent or treat COVID-19 could be a key tool to combat the pandemic. Merck ended its vaccine development in January.
PUBLIC HEALTH
Lebanon-Express

4 new COVID-19 Linn County deaths reported Thursday

Four new deaths connected to COVID-19 were reported in Linn County on Thursday, raising that county’s death total to 119. Benton County’s death toll remains at 30, with no new deaths reported. The Oregon Health Authority on Thursday reported 1,237 new positive and presumptive COVID-19 cases, bringing the state’s case...
LINN COUNTY, OR
americanmilitarynews.com

2 Navy SEALs, 16 other troops suing Biden, DOD over vaccine mandate

Liberty Counsel announced on Friday it has filed a class-action lawsuit against President Joe Biden, Secretary of Defense Lloyd Austin, Homeland Security Secretary Alejandro Mayorkas over the COVID-19 vaccine mandate. The suit was filed on behalf of 18 service members and several other federal and civilian contractors and employees. The...
AEROSPACE & DEFENSE
YOU MAY ALSO LIKE